<HashMap><database>ENA</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/062/SRR27840362/SRR27840362_1.fastq.gz</Fastqsanger.gz><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/061/SRR27840361/SRR27840361_1.fastq.gz</Fastqsanger.gz><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/063/SRR27840363/SRR27840363_1.fastq.gz</Fastqsanger.gz><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/064/SRR27840364/SRR27840364_1.fastq.gz</Fastqsanger.gz><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/066/SRR27840366/SRR27840366_1.fastq.gz</Fastqsanger.gz><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/062/SRR27840362/SRR27840362_2.fastq.gz</Fastqsanger.gz><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/064/SRR27840364/SRR27840364_2.fastq.gz</Fastqsanger.gz><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/061/SRR27840361/SRR27840361_2.fastq.gz</Fastqsanger.gz><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/065/SRR27840365/SRR27840365_2.fastq.gz</Fastqsanger.gz><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/065/SRR27840365/SRR27840365_1.fastq.gz</Fastqsanger.gz><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/066/SRR27840366/SRR27840366_2.fastq.gz</Fastqsanger.gz><Fastqsanger.gz>ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR278/063/SRR27840363/SRR27840363_2.fastq.gz</Fastqsanger.gz></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Genomics</omics_type><center_name>Population Health Sciences, UT Health Science Center at San Antonio</center_name><full_dataset_link>https://www.ebi.ac.uk/ena/browser/view/PRJNA1072101</full_dataset_link><scientific_name>Homo sapiens</scientific_name><tag>xref:PubMed:39258975</tag><long_description>We examined the significance and therapeutic potential of targeting PELP1 in Hepatocellular carcinoma. Total RNA were isolated from HEP3B-control Sh, and HEP3B-PELP1-Sh cells using RNeasy mini kit, and total RNA was isolated for RNA-seq analysis. Our results demonstrated that PELP1 knockdown regulates pathways related to inflammation and interferon signaling and downregulates several pathways including MYC and E2F. Overall design: Total RNA were isolated from Hep3B-control Sh, and Hep3B-PELP1-Sh using RNeasy mini kit (Qiagen). For whole-genome transcriptome profiling, 2 libraries (3 replicates from each group) were generated using a TruSeq Stranded mRNA Library Preparation kit according to the manufacturer’s protocol (Illumina Inc.). Samples were sequenced on the Illumina HiSeq 3000 platform (Illumina Inc.) using the 50 base-pair single-read (50SR) sequencing module.</long_description><repository>ENA</repository></additional><is_claimable>false</is_claimable><name>The therapeutic potential and significance of the PELP1 signaling pathway in hepatocellular carcinoma</name><description>The therapeutic potential and significance of the PELP1 signaling pathway in hepatocellular carcinoma</description><dates><last_updated>2025-09-24</last_updated><first_public>2024-10-18</first_public></dates><accession>PRJNA1072101</accession><cross_references><GEO>GSE254860</GEO><taxon>9606</taxon><PubMed>39258975</PubMed></cross_references></HashMap>